These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37794168)

  • 1. Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression.
    Gravas S; Manuel-Palacios J; Chavan C; Roehrborn CG; Oelke M; Averbeck MA; Biswas A; García LM; Mohamed K; Cortes V
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):469-477. PubMed ID: 37794168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.
    Gravas S; Palacios-Moreno JM; Thompson D; Concas F; Kamola PJ; Roehrborn CG; Oelke M; Kattan MW; Averbeck MA; Manyak M; Cortés V; Lulic Z
    Eur Urol Focus; 2023 Jan; 9(1):178-187. PubMed ID: 35985933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
    Gorgel SN; Sefik E; Kose O; Olgunelma V; Sahin E
    Int Braz J Urol; 2013; 39(5):657-62. PubMed ID: 24267123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Male patients with a higher frequency of nocturnal urinary episodes are more likely to benefit from alpha-blocker therapy for bothersome nocturia.
    Lee CL; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O174-O179. PubMed ID: 30548822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can We Rely Solely on the International Prostate Symptoms Score to Investigate Storage Symptoms in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement? Findings from a Cross-sectional Study.
    Pozzi E; Boeri L; Capogrosso P; Cazzaniga W; Candela L; Fallara G; Schifano N; Costa A; Cignoli D; Tutolo M; Matloob R; Abbate C; Montorsi F; Salonia A
    Eur Urol Focus; 2022 Mar; 8(2):555-562. PubMed ID: 33757736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
    World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study.
    Oelke M; Roehrborn CG; D'Ancona C; Wilson TH; Castro R; Manyak M
    World J Urol; 2014 Oct; 32(5):1133-40. PubMed ID: 24804842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
    Lojanapiwat B; Permpongkosol S
    Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
    Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
    Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? : A prospective, randomized, controlled trial.
    Yan M; Xue P; Wang K; Gao G; Zhang W; Sun F
    Strahlenther Onkol; 2017 Sep; 193(9):714-721. PubMed ID: 28612083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.
    Angalakuditi M; Seifert RF; Hayes RP; O'Leary MP; Viktrup L
    Health Qual Life Outcomes; 2010 Nov; 8():131. PubMed ID: 21073697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
    Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
    Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Monotherapies and Combination Therapy of Tamsulosin and Tadalafil for Treating Lower Urinary Tract Symptoms Caused by Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Meta-Analysis.
    Liu J; Zhou W; Zhang P; Zhang W; Chang C; Fu G
    Urol Int; 2024; 108(2):89-99. PubMed ID: 38081154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Effects of Oral Supplementation of Gamma-Cyclodextrin Curcumin Complex in Male Patients with Moderate-To-Severe Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms.
    Crocerossa F; Cantiello F; Bagalá L; Sicoli F; Carbonara U; Manfredi C; Falagario U; Veccia A; Pandolfo SD; Napolitano L; Ferro M; Di Dio M; Mondaini N; Damiano R
    Urol Int; 2023; 107(10-12):924-934. PubMed ID: 37939691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The α1 adrenoceptor antagonist tamsulosin for the treatment of voiding symptoms improves nocturia and sleep quality in women.
    Kim SO; Choi HS; Kwon D
    Urol J; 2014 Jul; 11(3):1636-41. PubMed ID: 25015610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.